Reviewing Lotus Pharmaceuticals (OTCMKTS:LTUS) & Y-mAbs Therapeutics (NASDAQ:YMAB)

Y-mAbs Therapeutics (NASDAQ:YMAB) and Lotus Pharmaceuticals (OTCMKTS:LTUS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Profitability

This table compares Y-mAbs Therapeutics and Lotus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	-28.22%	-24.61%	-18.49%
Lotus Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Y-mAbs Therapeutics and Lotus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	1	0	7	2	3.00
Lotus Pharmaceuticals	0	0	0	0	0.00

Y-mAbs Therapeutics presently has a consensus target price of $20.89, indicating a potential upside of 242.44%. Given Y-mAbs Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Y-mAbs Therapeutics is more favorable than Lotus Pharmaceuticals.

Earnings & Valuation

This table compares Y-mAbs Therapeutics and Lotus Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	$84.55 million	3.23	-$21.43 million	($0.54)	-11.30
Lotus Pharmaceuticals	N/A	N/A	-$20,000.00	N/A	N/A

Lotus Pharmaceuticals has lower revenue, but higher earnings than Y-mAbs Therapeutics.

Risk and Volatility

Y-mAbs Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of -2.13, suggesting that its share price is 313% less volatile than the S&P 500.

Institutional & Insider Ownership

70.8% of Y-mAbs Therapeutics shares are held by institutional investors. 22.5% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Y-mAbs Therapeutics beats Lotus Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

About Lotus Pharmaceuticals

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.